Crescent Biopharma (FRA:C68) Total Liabilities: €13.22 Mil (As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
10 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Total Liabilities?

Crescent Biopharma FRA:C68 10 Total Liabilities is €13.22 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's Total Liabilities for the quarter that ended in Mar. 2026 was €13.22 Mil.

Crescent Biopharma's quarterly Total Liabilities increased from Sep. 2025 (€18.43 Mil) to Dec. 2025 (€31.84 Mil) but then declined from Dec. 2025 (€31.84 Mil) to Mar. 2026 (€13.22 Mil).

Crescent Biopharma's annual Total Liabilities increased from . 20 (€0.00 Mil) to Dec. 2024 (€48.80 Mil) but then declined from Dec. 2024 (€48.80 Mil) to Dec. 2025 (€31.84 Mil).

Crescent Biopharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Total Liabilities Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Total Liabilities
48.80 31.84

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial 0.00 15.76 18.43 31.84 13.22
FRA:C68
10GF Score
Crescent Biopharma Inc FRA:C68
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Crescent Biopharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=30.805+(1.032+0.0010000000000012
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=31.84

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=205.21-173.372
=31.84

Crescent Biopharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.277+(0.943+1.4432899320127E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=13.22

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=172.247-159.028
=13.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €13.22 Mil mean?
Crescent Biopharma (FRA:C68) has a Total Liabilities of €13.22 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Crescent Biopharma and its competitors.
Is Crescent Biopharma's Total Liabilities too high?
Crescent Biopharma's current Total Liabilities is €13.22 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Total Liabilities compare to KYTX and ZURA?
Crescent Biopharma's Total Liabilities of €13.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Crescent Biopharma and its competitors. Crescent Biopharma's current Total Liabilities is €13.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Total Liabilities of €13.22 Mil. The current Total Liabilities is €13.22 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Total Liabilities is €13.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for FRA:C68

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price